OOIR: Observatory of International Research

Papers

(The H4-Index of JACC-Heart Failure is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality	197
A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock	171
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction	158
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF	137
Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease	137
Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation	97
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction	94
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes	92
Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19	88
Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy	78
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists	77
Advanced Heart Failure Epidemiology and Outcomes	71
COVID-19 in Heart Transplant Recipients	68
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy	66
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes	59
Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes	59
Hemocompatibility-Related Adverse Events and Survival on Venoarterial Extracorporeal Life Support	57
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure	56
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF	54
A Pragmatic Approach to Weaning Temporary Mechanical Circulatory Support	54
Renal Compression in Heart Failure	52
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction	48
Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients	47
Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF	46
Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure	45

Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines	45
Timing of Active Left Ventricular Unloading in Patients on Venoarterial Extracorporeal Membrane Oxygenation Therapy	43
The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials	41
Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction	40
Acute Myocarditis Associated With Desmosomal Gene Variants	39
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis	36
Prediction of Survival After Implantation of a Fully Magnetically Levitated Left Ventricular Assist Device	36
ECMO as a Bridge to Left Ventricular Assist Device or Heart Transplantation	35
Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction	35
Drug Layering in Heart Failure	34
Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure	34